Rituximab – The first twenty years

Leandro, Maria; Isenberg, David

doi:10.1177/0961203320982668

Cited by 22 publications

(13 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mode of action RTX targets CD 20 on activated B cells and impairs new antibody production and B cell-mediated helper function. It has been used extensively for lymphoma and some systemic autoimmune diseases (97).…”

Section: Rituximabmentioning

confidence: 99%

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

Burch

Perros

Bednarczuk

et al. 2022

European Thyroid Journal

View full text Add to dashboard Cite

Thyroid eye disease (TED) remains challenging for clinicians to evaluate and manage. Novel therapies have recently emerged, and their specific roles are still being determined. Most patients with TED develop eye manifestations while being treated for hyperthyroidism and under the care of endocrinologists. Endocrinologists, therefore, have a key role in diagnosis, initial management, and selection of patients who require referral to specialist care. Given that the need for guidance to endocrinologists charged with meeting the needs of patients with TED transcends national borders, and to maximize an international exchange of knowledge and practices, the American Thyroid Association and European Thyroid Association joined forces to produce this Consensus Statement.

show abstract

Section: Rituximabmentioning

confidence: 99%

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

Burch

Perros

Bednarczuk

et al. 2022

European Thyroid Journal

View full text Add to dashboard Cite

show abstract

“…non-Hodgkin lymphoma, chronic lymphoid leukemia, rheumatoid arthritis, Wegener granulomatosis, microscopic polyangiitis, and pemphigus vulgaris) thanks to ICD-10 codes for LTD status or any discharge diagnosis linked to a hospitalization within the 5 years preceding the index date. We also identified offlabel indications of rituximab (including, among others, lupus [24], multiple sclerosis [25], and kidney disease [26]) with corresponding ICD-10 codes. ICD-10 codes used for these steps are presented in Online Resource Table 2.…”

Section: Patient Characteristicsmentioning

confidence: 99%

Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System

Jourdain¹,

Hoisnard

Sbidian

et al. 2023

BioDrugs

View full text Add to dashboard Cite

Background Biosimilar products of rituximab came to market in 2017. French pharmacovigilance centers have highlighted an excess of case reports of severe hypersensitivity reactions related to their use compared with the originator product. Objective The aim of this study was to assess the real-world association between biosimilar versus originator rituximab injections and hypersensitivity reactions, among initiators and switchers, at first injection and over time. Methods The French National Health Data System was used to identify all rituximab users between 2017 and 2021. A first cohort consisted of patients who initiated rituximab (originator or biosimilar), while a second cohort consisted of originatorto-biosimilar switchers, matched on age, sex, deliveries history, and pathology, with one or two patients still receiving the originator product. The event of interest was defined as a hospitalization for anaphylactic shock or serum sickness following a rituximab injection. Results A total of 91,894 patients were included in the initiation cohort-17,605 (19%) with the originator product and 74,289 (81%) with a biosimilar. At initiation, 86/17,605 (0.49%) and 339/74,289 (0.46%) events occurred in the originator and biosimilar groups, respectively. The adjusted odds ratio of biosimilar exposure associated with the event was 1.04 (95% confidence interval [CI] 0.80-1.34), and the adjusted hazard ratio for biosimilar versus originator exposure was 1.15 (95% CI 0.93-1.42), showing no increased risk of event with biosimilar use at first injection, and over time. 17,123 switchers were matched to 24,659 non-switchers. No association was found between switch to biosimilars and occurrence of the event. Conclusion Our study does not support any association between exposure to rituximab biosimilars versus originator and hospitalization for a hypersensitivity reaction, either at initiation, at switch, or over time.

show abstract

“…Rituximab (RTX) is a monoclonal antibody directed against the B-cell-specific antigen CD20 that acts as an efficient depleter of B cells in peripheral blood [ 82 ]. According to European guidelines, RTX should be considered in patients with AIP-1 if they are resistant to or cannot tolerate high-dose GC or have not responded to immunomodulatory therapies (IM).…”

Section: Therapymentioning

confidence: 99%

Autoimmune Pancreatitis: From Pathogenesis to Treatment

Nista

Lucia

Manilla

et al. 2022

IJMS

View full text Add to dashboard Cite

Autoimmune pancreatitis (AIP) is a rare disease. The diagnosis of AIP is difficult and should be made by a comprehensive evaluation of clinical, radiological, serological, and pathological findings. Two different types of AIP have been identified: autoimmune pancreatitis type 1 (AIP-1), which is considered a pancreatic manifestation of multiorgan disease related to IgG4, and autoimmune pancreatitis type 2 (AIP-2), which is considered a pancreas-specific disease not related to IgG4. Although the pathophysiological conditions seem to differ between type 1 and type 2 pancreatitis, both respond well to steroid medications. In this review, we focused on the pathogenesis of the disease to develop a tool that could facilitate diagnosis and lead to the discovery of new therapeutic strategies to combat autoimmune pancreatitis and its relapses. The standard therapy for AIP is oral administration of corticosteroids. Rituximab (RTX) has also been proposed for induction of remission and maintenance therapy in relapsing AIP-1. In selected patients, immunomodulators such as azathioprine are used to maintain remission. The strength of this review, compared with previous studies, is that it focuses on the clear difference between the two types of autoimmune pancreatitis with a clearly delineated and separate pathogenesis. In addition, the review also considers various therapeutic options, including biologic drugs, such as anti-tumor necrosis factor (TNF) therapy, a well-tolerated and effective second-line therapy for AIP type 2 relapses or steroid dependence. Other biologic therapies are also being explored that could provide a useful therapeutic alternative to corticosteroids and immunosuppressants, which are poorly tolerated due to significant side effects.

show abstract

Rituximab – The first twenty years

Cited by 22 publications

References 62 publications

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System

Autoimmune Pancreatitis: From Pathogenesis to Treatment

Contact Info

Product

Resources

About